Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution
Author:
Funder
Fonds de Recherche du Québec - Santé
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Clinical Neurology,Neurology,Oncology
Link
http://link.springer.com/article/10.1007/s11060-017-2383-2/fulltext.html
Reference39 articles.
1. Minniti G et al (2010) Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 97(3):377–381
2. Batchelor TT et al (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31(26):3212–3218
3. Wick W et al (2010) Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28(7):1168–1174
4. Reardon DA et al (2012) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naive, recurrent glioblastoma. J Neurooncol 107(1):155–164
5. Wong ET et al (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17(8):2572–2578
Cited by 61 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prognostic Factors for Progression-free Survival and Overall Survival After Recurrence of Glioblastoma;Anticancer Research;2024-06-26
2. Tumour growth rate predicts overall survival in patients with recurrent WHO grade 4 glioma;BMC Medical Imaging;2024-05-27
3. Association of 5-aminolevulinic acid fluorescence guided resection with photodynamic therapy in recurrent glioblastoma: a matched cohort study;Acta Neurochirurgica;2024-05-13
4. Multiple surgical resections for progressive IDH wildtype glioblastoma—is it beneficial?;Acta Neurochirurgica;2024-03-15
5. Can Platelet-to-Lymphocyte Ratio (PLR) and Neutrophil-to-Lymphocyte Ratio (NLR) Help Predict Outcomes of Patients With Recurrent Glioblastoma?;In Vivo;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3